Breast Cancer Res. 2005;7(2):48-51. Epub 2005 Jan 12.

Clinical trial update: National Cancer Institute of Canada.

Source

Toronto Sunnybrook Regional Cancer Centre. kathy.pritchard@sw.ca

Abstract

The Breast Cancer Site Group (BCSG) of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) has conducted a wide variety of clinical trials focussing on large phase III trials of adjuvant chemotherapy, adjuvant hormonal therapy, and optimal delivery of adjuvant radiation therapy. The Group has also fostered, together with the NCIC CTG Investigational New Drug (IND) Program, a series of phase II and phase I/II studies which will be carried through if possible, into the phase III setting.

PMID:: 15743510; [PubMed - indexed for MEDLINE]
PMCID: PMC1064133

Free PMC Article

Images from this publication.See all images (3) Free text

Publication Types, MeSH Terms

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Libraries

LinkOut Holdings

Supplemental Content

Related citations

Clinical cooperative trials of the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. [Cancer. 1994]
Clinical cooperative trials of the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.
Pritchard KI. Cancer. 1994 Aug 1; 74(3 Suppl):1150-5.
Review Adjuvant systemic therapy for breast cancer. [Curr Opin Oncol. 1996]
Review Adjuvant systemic therapy for breast cancer.
Piccart MJ, Biganzoli L, Roy JA. Curr Opin Oncol. 1996 Nov; 8(6):478-84.
Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5. [J Clin Oncol. 2005]
Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.
Parulekar WR, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V, Levine M, Pritchard KI, National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2005 Sep 1; 23(25):6002-8.
Timing the collaborative analysis of three trials comparing 5-FU plus folinic acid (FUFA) to surgery alone in the management of resected colorectal cancer: a National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) perspective. [Stat Med. 1994]
Timing the collaborative analysis of three trials comparing 5-FU plus folinic acid (FUFA) to surgery alone in the management of resected colorectal cancer: a National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) perspective.
Pater JL. Stat Med. 1994 Jul 15-30; 13(13-14):1337-40.
Review [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Chemotherapy: the example of clinical studies]. [Suppl Tumori. 2004]
Review [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Chemotherapy: the example of clinical studies].
Sdrobolini A. Suppl Tumori. 2004 Jul-Aug; 3(4):S77-8.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Free in PMC
Free full text articles in PMC

Recent activity

Clear Turn Off Turn On

Clinical trial update: National Cancer Institute of Canada.
Clinical trial update: National Cancer Institute of Canada.
Breast Cancer Res. 2005 ;7(2):48-51. Epub 2005 Jan 12 .

PubMed
Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative ...
Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.
Cancer Res. 2004 May 15 ;64(10):3525-32.

PubMed
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 over...
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Clin Cancer Res. 2004 Oct 15 ;10(20):6779-88.

PubMed
The effect of surgical wounding on tumour development.
The effect of surgical wounding on tumour development.
Eur J Surg Oncol. 1999 Jun ;25(3):231-43.

PubMed
A divergent role for estrogen receptor-beta in node-positive and node-negative b...
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.
Breast Cancer Res. 2008 ;10(5):R74. Epub 2008 Sep 4 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: